Article Text

Download PDFPDF

1105 A novel triple action and pre-clinical safety profile of SLC-3010 predict its favorable translation in the phase I clinical study
  1. Woong Hee Yoon,
  2. Junhyeok Heo,
  3. Daeun Kim,
  4. Geona Kim,
  5. Kyungmi Han and
  6. Jun-Young Lee
  1. Selecxine, Seoul, Korea, Republic of


Background SLC-3010 is a noncovalent conjugate of IL-2 and anti-IL-2 antibody (TCB2) that can preferentially stimulate CD8 T cells and NK cells over Tregs. It is achieved by blocking the binding of IL-2 to the IL-2Rα, which is predominantly expressed on the Tregs. Previously we have reported that SLC-3010 exhibited strong anti-tumor activity in various mouse tumor models.1 Notably, the dissociated TCB2 persisted in serum for several weeks despite the clearance of SLC-3010 within 72 h. We hypothesized that the dissociated TCB2 can intercept the endogenous IL-2, thereby suppressing the Tregs while stimulating the CD8 T cells and NK cells. Such versatility was termed as the triple action, and the proof-of-concept studies were conducted. GLP toxicity and pharmacodynamic studies were also performed, which provided promising results for the safety and efficacy.

Methods GMP batch of SLC-3010 was manufactured at GenScript Probio. POC studies for the triple action were performed in mice either by administrating the anti-mouse IL-2 antibody (S4B6, functional substitute of TCB2 in mice) after the SLC-3010 to measure the Treg suppression, and by injecting the TCB2 several weeks ahead of IL-2 to validate the re-conjugation of TCB2 with the endogenous IL-2. GLP PK, PD, and toxicology assessments were conducted in mice or cynomolgus monkeys after i.v. injecting various doses of SLC-3010 or TCB2.

Results The potency of the dissociated TCB2 to enable the additional anti-cancer mechanisms was studied in mice. Co-treatment of SLC-3010 and S4B6 reduced the number of Tregs and Foxp3 expression, which is a functional indicator of Treg. In addition, TCB2 remained for weeks and reinitiated the immunostimulatory function upon the IL-2 encounter. GLP PK and PD studies in the cynomolgus monkeys demonstrated the selective expansion of CD8 T cells and NK cells. Adverse effects were unobserved in all dose groups of mice and monkeys in the pathological aspects. Half-lives of SLC-3010 were approximately 14 and 8 hours in mice and monkeys, respectively.


  • SLC-3010 is a noncovalent conjugate of IL-2 and TCB2, of which nature enables the “triple action” including the selective stimulation of anti-cancer immunity, disruption of Treg homeostasis, and re-boosting the immune system through the conjugation with the endogenous IL-2.

  • Favorable GLP toxicity results provided a large safety margin, with the NOAEL being over 30 folds greater than the initial dose (DL1) of the phase 1 clinical trial.

Acknowledgements We thank to the Pohang Institute of Science and Technology (POSTECH) for generously providing the research facilities. We are also grateful for Dr. Jae-Ho Cho for the scientific collaboration and the support.


  1. Lee JY, Lee E, Hong SW, et al. TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity. Oncoimmunology. 2020;9:e1681869.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.